VYNE Therapeutics to Present at the Cowen 41st Annual Health Care Conference

Rhea-AI Summary

VYNE Therapeutics Inc. announced that CEO David Domzalski will present at the Cowen 41st Annual Health Care Conference on March 2, 2021, at 2:10 PM ET. The presentation will be in a fireside chat format, providing insights into the company's innovative therapies in dermatology, including AMZEEQ® and ZILXI®, both FDA-approved minocycline products. For those interested, the webcast link is here. VYNE aims to enhance the lives of patients through proprietary therapies.

BRIDGEWATER, N.J., March 01, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present and participate at the Cowen 41^st Annual Health Care Conference.

Presentation details can be found below.

Day:	Tuesday, March 2, 2021
Time:	2:10pm Eastern Time
Format:	Fireside chat
Webcast Link:	https://wsw.com/webcast/cowen81/vyne/1982826

About VYNE Therapeutics Inc.
VYNE’s mission is to improve the lives of patients by developing proprietary, innovative and differentiated therapies in dermatology and beyond.

With expertise in topical medicine innovation as a springboard, VYNE is working to develop and commercialize a variety of solutions using its proprietary Molecule Stabilizing Technology (MST™), and has received FDA approval for AMZEEQ® (minocycline) topical foam, 4%, the world’s first topical minocycline, and for ZILXI® (minocycline) topical foam, 1.5%, the first minocycline product of any kind to be approved by the FDA for use in rosacea. For more information about our approved products, please see AMZEEQ’s Full Prescribing Information at AMZEEQ.com and ZILXI’s Full Prescribing Information at ZILXI.com.

For more information about VYNE Therapeutics Inc. or its investigational products, visit www.vynetherapeutics.com or follow VYNE on Twitter. VYNE may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor VYNE’s website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission, public conference calls, and webcasts.

CONTACT:
Joyce Allaire
LifeSci Advisors, LLC
646-889-1200
jallaire@lifesciadvisors.com

Andrew Saik
Chief Financial Officer
VYNE Therapeutics
908-731-6180
Andrew.Saik@vynetx.com

FAQ

When is VYNE's presentation at the Cowen 41st Annual Health Care Conference?

VYNE's presentation will take place on March 2, 2021, at 2:10 PM Eastern Time.

How can I watch the VYNE Therapeutics presentation at the conference?

You can watch the presentation via the webcast link: https://wsw.com/webcast/cowen81/vyne/1982826.

What products has VYNE Therapeutics developed?

VYNE Therapeutics has developed AMZEEQ® (topical minocycline foam) and ZILXI® (minocycline topical foam) for dermatological use.

What is the significance of the Cowen Health Care Conference for VYNE?

The Cowen Health Care Conference is an important platform for VYNE to showcase its innovative therapies and engage with investors.

Who is presenting on behalf of VYNE at the Cowen Conference?

David Domzalski, the CEO of VYNE Therapeutics, will be presenting at the conference.